Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.

Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.

Item
http://www.wikidata.org/entity/Q42659330
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate CancerNon-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer MetabolismThe biology of castration-resistant prostate cancerThe role of HOXC6 in prostate cancer development.A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancerTriptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients.Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.The PCAT3/PCAT9-miR-203-SNAI2 axis functions as a key mediator for prostate tumor growth and progression.Urinary markers aiding in the detection and risk stratification of prostate cancer
P2860

Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.

Item
http://www.wikidata.org/entity/Q42659330
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Evaluation of urinary prostate ...... nd metastatic prostate cancer.
@en
Evaluation of urinary prostate cancer antigen-3
@nl
type
label
Evaluation of urinary prostate ...... nd metastatic prostate cancer.
@en
Evaluation of urinary prostate cancer antigen-3
@nl
prefLabel
Evaluation of urinary prostate ...... nd metastatic prostate cancer.
@en
Evaluation of urinary prostate cancer antigen-3
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Evaluation of urinary prostate ...... nd metastatic prostate cancer.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698